Inavir laninamivir: Phase III data

A double-blind, Japanese Phase III trial in >1,500 healthy family members of a patient with confirmed influenza infection A or B infection showed that both dose regimens of Inavir met the primary endpoint of reducing the incidence of influenza infection vs. placebo (p<0.0001). Biota said a protective efficacy of >=70% was required to meet the endpoint. Inavir was well tolerated. Daiichi Sankyo plans to seek Japanese regulatory approval of Inavir for the prophylactic indication by year end. The pharma, which has Japanese rights to Inavir from Biota, markets the product in Japan to treat influenza A and B infection in adults and children. ...